Abl kinase domain (blue) in complex with<unk>  (red)<unk>  inhibits the kinases BCR-ABL, KIT, LCK, EPHA3, EPHA8, DDR1, DDR2, PDGFRB, MAPK11 and ZAK. Structurally related to imatinib, It is 10–30 fold more potent than imatinib in inhibiting Bcr-Abl tyrosine kinase activity and proliferation of Bcr-Abl expressing cells.
Nilotinib
Icotinib
Crizotinib
Tepotinib
Afatinib
Erlotinib
Axitinib
Imatinib